Alnylam Pharmaceuticals (ALNY) Tax Provisions (2009 - 2026)

Alnylam Pharmaceuticals' Tax Provisions history runs 14 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• Quarterly Tax Provisions fell 1.39% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 110.71% YoY) and the FY2025 annual result came in at $9.4 million, up 109.47% from the prior year.
• Tax Provisions was $15.7 million for Q1 2026 at Alnylam Pharmaceuticals, up from -$25.3 million in the prior quarter.
• Across five years, Tax Provisions topped out at $30.9 million in Q2 2025 and bottomed at -$110.2 million in Q4 2024.
• A 5-year average of -$3.7 million and a median of $1.8 million in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2023 — Tax Provisions soared 13091.3% — and 2024, when it slumped 60315.85%.
• Alnylam Pharmaceuticals' Tax Provisions stood at $472000.0 in 2022, then plunged by 61.23% to $183000.0 in 2023, then slumped by 60315.85% to -$110.2 million in 2024, then soared by 77.05% to -$25.3 million in 2025, then soared by 161.94% to $15.7 million in 2026.
• Business Quant data shows ALNY's Tax Provisions at $15.7 million in Q1 2026, -$25.3 million in Q4 2025, and -$12.1 million in Q3 2025.